These findings suggest that targeting the FABP5/PPARα axis may offer a therapeutic strategy for mitigating inflammation and cellular stress linked to obesity and metabolic disorders. The gene discussed is FABP5; the disease is obesity due to melanocortin 4 receptor deficiency.